Group items tagged

Pharmacy Business will be hosting their annual awards event in the pharmacy calendar with a glittering ceremony to celebrate the very best of community pharmacy. The 23rd edition of the Pharmacy Business Awards will be on Wednesday 4 October 2023 in central London. The awards attract the biggest names in pharmacy, with heads of pharmacy organisations, CEOs of leading manufacturers and wholesalers, health officials and government ministers in attendance. We look forward to bringing together the shining lights of community pharmacy, who show the nation the unique services they continue to provide. REASONS TO ATTEND Understand what the ambitions of the NHS and PSNC are for the future of community pharmacy Understand why its important to develop a wider range of health services Learn how others are achieving this and what the benefits can be Learn what the benefits of embracing technological innovations are Hear what others are doing and what the benefits are to their business Network with and learn from your peers in community pharmacy WHO SHOULD ATTEND? Pharmacy owners Pharmacy managers Other pharmacy stakeholders Exciting news! Pharmacy Business Awards 2023 are just around the corner!

In its response to a Freedom of Information Request (FOI), the NHS Business Services Authority (NHSBSA) has confirmed a net decrease of 101 pharmacies in England - with 371 closures and 270 new contracts. Meanwhile, the General Pharmaceutical Council data projected a drop of 43 registered pharmacies in England, Wales, and Scotland for the year ending March 31, 2023, compared to the preceding period. The data, released by business advisor Christie & Co in its annual pharmacy market review on Sept. 5, revealed a total of 14,328 pharmacies across all four UK country regions as of March 31, 2023, indicating a 0.3 per cent decrease from the previous year. Corporate operators experienced a net reduction of 249 pharmacies, while the total number of independent operators remained consistent with 2022. According to the study, the corporate sector saw the most substantial shift, with a 13.7 per cent reduction in businesses operating 300 or more pharmacies. Following closely, groups managing 11 to 15 pharmacies experienced a 5.6 per cent decrease. Christie & Co attributed this shift in group size to operators acquiring additional pharmacies through corporate disposal opportunities throughout the year.

The Company Chemists' Association (CCA) has highlighted a worrying trend of increasing numbers of pharmacy closures in England, which is disproportionately affecting the most deprived communities in the country. With 338 more pharmacies closed this year, an average of eight pharmacies closed per week, there has been a net loss of 1,008 pharmacies in England since 2015, the CCA said. Between 2015 and June 2023, maximum number of pharmacies were closed in the 20 per cent most deprived neighbourhoods of the country, with 37.5 per cent of the total closures occurring in Indices of Multiple Deprivation deciles 1 and 2. The association has raised concern that "permanent closures will undermine healthcare accessibility in deprived areas, where access tends to be more limited despite greater need."

As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges. As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology, big data, sustainability, ongoing policy changes and a shift in investment due to inflation. Utilising big data and tech Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare providers leveraging remote access further.

Alphega Pharmacy Oncology Support Programme allows community pharmacists from six European countries to enhance support and guidance they provide to cancer patients. The programme aims to help upskill pharmacists and their teams to provide more expert advice to patients living with cancer, raising their profile in the community as key healthcare providers. Enhancing knowledge amongst community pharmacists about cancer treatment and its side effects is vital as cancer cases are set to increase if current trends continue. The programme covers practical help topics, such as oral care, nutrition advice and skin, hair and nail care among others, helping patients to get more of the support they need because community pharmacists are easily accessible, rather than needing to book a GP or consultant appointment. With rates of cancer forecast to rise throughout Europe , and cancer patients likely on average to visit hospital less often, community pharmacists are well-placed to look to support cancer patients with managing the side-effects of their treatment.

In a recent survey of 2,000 UK adults, 34 per cent preferred consulting pharmacists for health advice after researching symptoms, while for those surveyed specifically from Wales, this figure increased to 35 per cent, according to 2San - a global supplier of healthcare products and solutions. The survey said women had a higher tendency, with 39 per cent seeking their pharmacist's guidance compared to 29 per cent of men surveyed. According to the survey findings, over one-fifth of people in the UK are turning to pharmacists instead of their primary care physician or doctor for guidance and advice with medical symptoms. "With more than 38 million patients in the UK waiting more than two weeks for a GP appointment, it is unsurprising that 34 per cent of people surveyed asked a pharmacist for advice over their primary care physician/doctor in the last 12 months," 2san said. In Wales, over a third of people prefer their community pharmacist for support and advice, while those aged 65 and above still tend to consult their primary care physician.

The Department of Health and Social Care (DHSC) has announced 30 pence increase in prescription charges from £9.35 to £9.65 for each medicine or appliance dispensed. Board Chair for England at RPS, Thorrun Govind commented: "This is a kick in the teeth for people in England who are already struggling with rising bills and food prices. "Patients groups have warned that people are not collecting prescription medicines due to cost and pharmacists are seeing this worrying trend first-hand. "A Government impact assessment noted the risk of adverse effects of people not taking their medicines, resulting in future health problems for the individual, potential hospital admissions, and a subsequent cost to the NHS. "This decision seems to prioritise revenue generation over ill-health prevention and undermines the principle of an NHS free at the point of use.

Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands Company, a company owned by American private equity firm Yellow Wood Partners. The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer, valued at around $80 million. Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt. ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024. Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being rigorous and disciplined where there are opportunities for divestment. "While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.

Medical sector has the third highest number of businesses currently for sale, with hospitality and retail technology firms most likely to sell up next year, according to the UK Business Investment Report. There are 4,300 registered medical businesses in the UK, and approximately 355 (one in every 12.11) are currently up for sale. Topping the list was the hospitality sector with one in every 9.88 businesses up for sale, ahead of retail technology businesses (1 in 10.13). At the bottom of the table were owners of agriculture businesses with just one in every 943 businesses up for sale. Transportation and software/IT business owners followed in a similar manner with one in every 802 businesses being up for sale.